<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin ACK</submitter><funding>The Second Century Fund (C2F), Chulalongkorn University</funding><funding>Thailand Science Research and Innovation Fund</funding><pagination>20858</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9718795</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>Caffeic acid derivatives containing amide moieties similar to those of finasteride and dutasteride were synthesized. An in vitro inhibitory activity evaluation of caffeic acid (1) and its amide derivatives (2 - 4) against the steroid 5α-reductase type 1 (SRD5A1) produced by human keratinocyte cells coupled with the non-radioactive high-performance thin-layer chromatography detection revealed that caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide (4) was a promising non-steroidal suppressor, with a half-maximal inhibitory concentration (IC&lt;sub>50&lt;/sub>) of 1.44 ± 0.13 µM and relatively low cytotoxicity with an IC&lt;sub>50&lt;/sub> of 29.99 ± 8.69 µM. The regulatory role of compound 4 against SRD5A1 involved both suppression of SRD5A1 expression and mixed mode SRD5A1 inhibition. The K&lt;sub>i&lt;/sub> value of compound 4 was 2.382 µM based on the whole-cell kinetic studies under specific conditions. Molecular docking and molecular dynamics simulations with AlphaFold generated the human SRD5A1 structure and confirmed the stability of compound 4 at the SRD5A1 catalytic site with greater interactions, including hydrogen bonding of the key M119 amino-acid residue than those of finasteride and dutasteride. Thus, compound 4 shows the potential for further development as an SRD5A1 suppressor for androgenic alopecia treatment.</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics.</pubmed_title><pmcid>PMC9718795</pmcid><funding_grant_id>CU_FRB640001_23_33_8</funding_grant_id><pubmed_authors>Netcharoensirisuk P</pubmed_authors><pubmed_authors>Chansriniyom C</pubmed_authors><pubmed_authors>Chaotham C</pubmed_authors><pubmed_authors>De-Eknamkul W</pubmed_authors><pubmed_authors>Sukma W</pubmed_authors><pubmed_authors>Rungrotmongkol T</pubmed_authors><pubmed_authors>Sanachai K</pubmed_authors><pubmed_authors>Lin ACK</pubmed_authors><pubmed_authors>Chamni S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics.</name><description>Caffeic acid derivatives containing amide moieties similar to those of finasteride and dutasteride were synthesized. An in vitro inhibitory activity evaluation of caffeic acid (1) and its amide derivatives (2 - 4) against the steroid 5α-reductase type 1 (SRD5A1) produced by human keratinocyte cells coupled with the non-radioactive high-performance thin-layer chromatography detection revealed that caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide (4) was a promising non-steroidal suppressor, with a half-maximal inhibitory concentration (IC&lt;sub>50&lt;/sub>) of 1.44 ± 0.13 µM and relatively low cytotoxicity with an IC&lt;sub>50&lt;/sub> of 29.99 ± 8.69 µM. The regulatory role of compound 4 against SRD5A1 involved both suppression of SRD5A1 expression and mixed mode SRD5A1 inhibition. The K&lt;sub>i&lt;/sub> value of compound 4 was 2.382 µM based on the whole-cell kinetic studies under specific conditions. Molecular docking and molecular dynamics simulations with AlphaFold generated the human SRD5A1 structure and confirmed the stability of compound 4 at the SRD5A1 catalytic site with greater interactions, including hydrogen bonding of the key M119 amino-acid residue than those of finasteride and dutasteride. Thus, compound 4 shows the potential for further development as an SRD5A1 suppressor for androgenic alopecia treatment.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-05-28T01:10:58.977Z</modification><creation>2025-04-19T22:48:54.302Z</creation></dates><accession>S-EPMC9718795</accession><cross_references><pubmed>36460729</pubmed><doi>10.1038/s41598-022-25335-7</doi></cross_references></HashMap>